Efficacy and safety of iGlarLixi versus standard of care in a real-world adult China population with uncontrolled type 2 Diabetes on oral agents-a pragmatic randomized controlled trial

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: 0503caba81a975d4a31ebbfaad06b5f103ac0a65
First added on: Apr 24, 2026